Trials (Cancer Institute Strasbourg Europe): Revision history

14 December 2025

• curprev 19:1219:12, 14 December 2025‎ Francine talk contribs‎ 60,901 bytes +170‎ No edit summary undo

6 December 2025

• curprev 12:4012:40, 6 December 2025‎ Lucas talk contribs‎ m 60,731 bytes +1,701‎ Update categories. undo

3 December 2025

• curprev 12:0012:00, 3 December 2025‎ Francine talk contribs‎ 59,030 bytes +48‎ No edit summary undo

2 December 2025

• curprev 13:5813:58, 2 December 2025‎ Lucas talk contribs‎ m 58,982 bytes +90‎ Update categories. undo

3 December 2023

• curprev 23:3023:30, 3 December 2023‎ Francine talk contribs‎ 58,892 bytes +58,892‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Cancer Institute Strasbourg Europe page '''NCTID''': NCT04717414 '''Title''': An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions '''Study Summary''': The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspa..."